Correlations between treatment response and survival in patients with advanced non–small-cell lung cancer (NSCLC) have been unclear. Now, investigators have conducted a meta-analysis of 14 randomized, controlled trials of targeted and standard NSCLC therapies to examine associations between overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) in 12,567 NSCLC patients.
At the trial level, ORR was strongly correlated with PFS (R2 =0.89), but no …